EZH2 regulates sFRP4 expression without affecting the methylation of sFRP4 promoter DNA in colorectal cancer cell lines

Liu,Yuting; Yu,Jun; Xie,Yang; Li,Mengying; Wang,Feng; Zhang,Jing; Qi,Jian

doi:10.3892/etm.2020.9160

EZH2 regulates sFRP4 expression without affecting the methylation of sFRP4 promoter DNA in colorectal cancer cell lines

Authors:
- Yuting Liu
- Jun Yu
- Yang Xie
- Mengying Li
- Feng Wang
- Jing Zhang
- Jian Qi
View Affiliations

Affiliations: Gastroenterology Center, The Seventh Affiliated Hospital of Sun Yat‑sen University, Guangming, Shenzhen 518000, P.R. China, Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430000, P.R. China
Published online on: September 1, 2020 https://doi.org/10.3892/etm.2020.9160
Article Number: 33
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormal activation of the Wnt signaling pathway is found in 90% of colorectal cancers (CRCs). Secreted frizzled‑related protein 4 (sFRP4) serves as an antagonist of the canonical Wnt signaling pathway. Epigenetic alterations, including changes in DNA methylation and histone methylation, may influence the expression of sFRP4. Polycomb group (PcG) proteins are epigenetic transcriptional repressors that selectively repress gene expression by forming polycomb repressive complexes (PRCs). Enhancer of zeste homolog 2 (EZH2), the core component of PRC2, is a histone‑lysine N‑methyltransferase that interacts with DNA methyltransferases. In the present study, the promoter DNA methylation status of sFRP4 in CRC cell lines was analyzed and the underlying mechanisms of action governing this modification was investigated. Firstly, the DNA methylation status of the sFRP4 promoter in CRC cell lines was assessed using methylation‑specific PCR. Subsequently, the mRNA and protein levels of sFRP4 were measured using real‑time qPCR and western blot analysis, respectively, to determine whether the DNA methylation status of the sFRP4 promoter is correlated with its transcriptional levels. To screen for important epigenetic modifiers that may regulate the promoter DNA methylation status of sFRP4, the expression levels of PcG proteins were examined by gene array analysis. ChIP‑qPCR was performed to test whether the selected PcG proteins directly bind the promoter region of sFRP4. Finally, the downregulated PcG proteins EZH2, chromobox 7 (CBX7) and jumonji and AT‑rich interaction domain containing 2 (JARID2) were identified and their association with sFRP4 expression levels and Wnt/β‑catenin signaling pathway activity were investigated. The present study revealed that sFRP4 was hypermethylated in the promoter region and downregulated during the progression of the CRC cell lines from Dukes A to Dukes C. Expression levels of PcG proteins EZH2, CBX7 and JARID2 were upregulated and positively associated with the aberrantly activated Wnt signaling pathway in the CRC cell lines. EZH2, CBX7 and JARID2 were all enriched in the sFRP4 promoter region in CRC cells. EZH2 downregulation did not affect the promoter DNA methylation status of sFRP4 but increased its expression levels and decreased CRC cell proliferation. DNA methylation controls the expression of sFRP4. EZH2 regulates sFRP4 expression without affecting the DNA hypermethylation of the sFRP4 promoter and influences CRC cell proliferation and Wnt/β‑catenin signaling pathway activities.

View Figures

View References

1	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.PubMed/NCBI View Article : Google Scholar
2	Nusse R and Clevers H: Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017.
3	Krishnamurthy N and Kurzrock R: Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 62:50–60. 2018.PubMed/NCBI View Article : Google Scholar
4	Cruciat CM and Niehrs C: Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 5(a015081)2013.PubMed/NCBI View Article : Google Scholar
5	Farooqi AA, de la Roche M, Djamgoz MBA and Siddik ZH: Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Semin Cancer Biol. 58:65–79. 2019.PubMed/NCBI View Article : Google Scholar
6	Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC and Plass C: CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 66:653–658. 2006.PubMed/NCBI View Article : Google Scholar
7	Rubin JS and Bottaro DP: Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clin Cancer Res. 13:4660–4663. 2007.PubMed/NCBI View Article : Google Scholar
8	Chong JM, Uren A, Rubin JS and Speicher DW: Disulfide bond assignments of secreted frizzled-related protein-1 provide insights about frizzled homology and netrin modules. J Biol Chem. 277:5134–5144. 2002.PubMed/NCBI View Article : Google Scholar
9	Deshmukh A, Arfuso F, Newsholme P and Dharmarajan A: Epigenetic demethylation of sFRPs, with emphasis on sFRP4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells. Int J Biochem Cell Biol. 109:23–32. 2019.PubMed/NCBI View Article : Google Scholar
10	Pawar NM and Rao P: Secreted frizzled related protein 4 (sFRP4) update: A brief review. Cell Signal. 45:63–70. 2018.PubMed/NCBI View Article : Google Scholar
11	Pohl S, Scott R, Arfuso F, Perumal V and Dharmarajan A: Secreted frizzled-related protein 4 and its implications in cancer and apoptosis. Tumour Biol. 36:143–152. 2015.PubMed/NCBI View Article : Google Scholar
12	Qi J, Zhu YQ, Luo J and Tao WH: Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 12:7113–7117. 2006.PubMed/NCBI View Article : Google Scholar
13	Michalak EM, Burr ML, Bannister AJ and Dawson MA: The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 20:573–589. 2019.PubMed/NCBI View Article : Google Scholar
14	Dor Y and Cedar H: Principles of DNA methylation and their implications for biology and medicine. Lancet. 392:777–786. 2018.PubMed/NCBI View Article : Google Scholar
15	Schübeler D: Function and information content of DNA methylation. Nature. 517:321–326. 2015.PubMed/NCBI View Article : Google Scholar
16	Samaei NM, Yazdani Y, Alizadeh-Navaei R, Azadeh H and Farazmandfar T: Promoter methylation analysis of WNT/β-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer. J Biomed Sci. 21(73)2014.PubMed/NCBI View Article : Google Scholar
17	Takeshima H, Wakabayashi M, Hattori N, Yamashita S and Ushijima T: Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 36:192–201. 2015.PubMed/NCBI View Article : Google Scholar
18	Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 359:198–205. 2015.PubMed/NCBI View Article : Google Scholar
19	Sarma DP: The Dukes classification of colorectal cancer. JAMA. 256(1447)1986.PubMed/NCBI
20	Coppedè F: Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation. Cancer Lett. 342:238–247. 2014.PubMed/NCBI View Article : Google Scholar
21	Baharudin R, Tieng FYF, Lee LH and Ab Mutalib NS: Epigenetics of SFRP1: The dual roles in human cancers. Cancers (Basel). 12(445)2020.PubMed/NCBI View Article : Google Scholar
22	Liu R, Su X, Long Y, Zhou D, Zhang X, Ye Z, Ma J, Tang T, Wang F and He C: A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. Mutat Res. 779:45–57. 2019.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Vincent KM and Postovit LM: Matricellular proteins in cancer: A focus on secreted frizzled-related proteins. J Cell Commun Signal. 12:103–112. 2018.PubMed/NCBI View Article : Google Scholar
25	Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J and Shipley J: JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene. 33:1148–1157. 2014.PubMed/NCBI View Article : Google Scholar
26	Yang Q, Huang T, Ye G, Wang B and Zhang X: Methylation of SFRP2 gene as a promising noninvasive biomarker using feces in colorectal cancer diagnosis: A systematic meta-analysis. Sci Rep. 6(33339)2016.PubMed/NCBI View Article : Google Scholar
27	Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 36:417–422. 2004.PubMed/NCBI View Article : Google Scholar
28	Stoll S, Wang C and Qiu H: DNA methylation and histone modification in hypertension. Int J Mol Sci. 19(1174)2018.PubMed/NCBI View Article : Google Scholar
29	Wang W, Qin JJ, Voruganti S, Nag S, Zhou J and Zhang R: Polycomb group (PcG) proteins and human cancers: Multifaceted functions and therapeutic implications. Med Res Rev. 35:1220–1267. 2015.PubMed/NCBI View Article : Google Scholar
30	Chan HL and Morey L: Emerging roles for polycomb-group proteins in stem cells and cancer. Trends Biochem Sci. 44:688–700. 2019.PubMed/NCBI View Article : Google Scholar
31	Piunti A and Shilatifard A: Epigenetic balance of gene expression by polycomb and COMPASS families. Science. 352(aad9780)2016.PubMed/NCBI View Article : Google Scholar
32	Colón-Caraballo M, Monteiro JB and Flores I: H3K27me3 is an epigenetic mark of relevance in endometriosis. Reprod Sci. 22:1134–1142. 2015.PubMed/NCBI View Article : Google Scholar
33	Liu M, Zhou J, Chen Z and Cheng ASL: Understanding the epigenetic regulation of tumours and their microenvironments: Opportunities and problems for epigenetic therapy. J Pathol. 241:10–24. 2017.PubMed/NCBI View Article : Google Scholar
34	Bogdanovic O, Long SW, van Heeringen SJ, Brinkman AB, Gómez-Skarmeta JL, Stunnenberg HG, Jones PL and Veenstra GJ: Temporal uncoupling of the DNA methylome and transcriptional repression during embryogenesis. Genome Res. 21:1313–1327. 2011.PubMed/NCBI View Article : Google Scholar
35	Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR and Hersey P: Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 40:328–344. 2019.PubMed/NCBI View Article : Google Scholar
36	Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li N, He JM, Xie GF, Xie X and Liang HJ: EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling. Oncotarget. 7:41540–41558. 2016.PubMed/NCBI View Article : Google Scholar
37	Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, et al: EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 71:4028–4039. 2011.
38	Chen Q, Zheng PS and Yang WT: EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma. Oncotarget. 7:36115–36129. 2016.PubMed/NCBI View Article : Google Scholar
39	Ma R, Wei Y, Huang X, Fu R, Luo X, Zhu X, Lei W, Fang J, Li H and Wen W: Inhibition of GSK 3β activity is associated with excessive EZH2 expression and enhanced tumour invasion in nasopharyngeal carcinoma. PLoS One. 8(e68614)2013.PubMed/NCBI View Article : Google Scholar
40	Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y and Helgason CD: Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin Epigenetics. 7(40)2015.PubMed/NCBI View Article : Google Scholar